Basal layer keratinocytes with reduced levels of peroxisome proliferator-activated receptor gamma initiate autoimmune inflammation across the lupus spectrum in mice, according to an experimental investigation published in Immunity & Inflammation. Investigators demonstrated that localized genetic deletion of Pparg restricted to basal epithelial cells provoked cutaneous lupus-like lesions, whereas broader deletion across the skin drove rapid progression into systemic autoimmunity characterized by multi-organ pathology, autoantibody elevation, and renal damage. The work identifies the skin epithelium as an initiating site capable of licensing migratory dendritic cells to propagate systemic autoimmune dysfunction.
Lupus spectrum disorders encompass cutaneous lupus erythematosus and systemic lupus erythematosus, representing heterogeneous autoimmune conditions characterized by compromised self-tolerance and widespread tissue inflammation. For decades, unraveling the precise initial triggers and transitions between skin-confined and systemic pathology has been hindered by existing animal models. Many classical systemic models such as MRL/lpr, NZB/W F1, BXSB/Yaa, and PD-1H-deficient mice develop autoantibodies and glomerulonephritis but rarely capture typical cutaneous disease or photosensitivity, while existing cutaneous models fail to progress systemically. The current study addressed this limitation by tracking the functional consequences of epithelial defects identified in human patient tissue.
The experimental study was motivated by clinical observations in cutaneous lesions from patients diagnosed with cutaneous lupus erythematosus and systemic lupus erythematosus. Re-analysis of published human cutaneous transcriptome datasets from the Gene Expression Omnibus, specifically datasets GSE72535, GSE100093, and GSE109248, revealed significant downregulation of the PPAR signaling pathway in lesion samples compared to healthy skin controls. Subsequent immunohistochemical staining confirmed that protein content of peroxisome proliferator-activated receptor gamma was markedly reduced in epidermal basal layer keratinocytes of human patients. Unlike inflammatory conditions such as psoriasis or atopic dermatitis that preserve basal layer PPAR gamma, lupus lesions showed a distinct and consistent basal loss across the disease spectrum.
To establish a tractable in vivo system mirroring this human lesion phenotype, the researchers bred immunocompetent C57BL/6J mice carrying floxed Pparg alleles with Krt5creERT2/+ transgenic mice, permitting conditional, inducible deletion of Pparg in basal keratinocytes upon exposure to tamoxifen or 4-hydroxytamoxifen. When five- to eight-week-old mice received systemic intraperitoneal tamoxifen injections once daily for five consecutive days, Cre-mediated excision produced severe lupus-like disease with 100 percent penetrance by day 11. These animals displayed pronounced cutaneous ulceration, alopecia, and erythema alongside severe systemic disease, including marked proteinuria, glomerular IgG deposition, elevated circulating autoantibodies, and mortality around days 12 to 13 post-induction.
To replicate localized human disease manifestations and refine animal survival, the research team administered 4-hydroxytamoxifen topically to both ears of the conditional knockout mice at a dose of 40 microliters daily for five days. This bilateral localized epidermal deletion triggered marked cutaneous inflammation by day 17, featuring typical histological hallmarks of interface dermatitis, follicular plugging, acanthosis, and hyperkeratosis. Concurrently, the mice developed chronic multifocal to segmental glomerulointerstitial nephritis, abundant renal immune complex deposition, elevated spleen indices, and substantial increases in serum antinuclear antibodies and anti-double-stranded DNA antibodies.
Flow cytometric analysis of splenic immune cells in these bilaterally treated mice demonstrated broad systemic immune dysregulation that mirrored clinical observations in human lupus patients. The researchers recorded significant expansions of CD4-positive T helper subsets, including Th1, Th2, Th17, and T follicular helper cells, accompanied by elevated regulatory T cells and a marked increase in splenic plasma cell populations. When left without further chemical induction, the animals showed gradual symptomatic improvement by day 21, characterized by waning dermatitis scores, lower urinary protein, and falling anti-dsDNA titers, mimicking clinical disease remission.
To provide a durable observation window suitable for preclinical testing, the investigators extended this bilateral model by administering an additional five-day regimen of topical 4-hydroxytamoxifen to the dorsal skin beginning on day 14. This second round sustained robust epithelial suppression of PPAR gamma, maintaining prominent dermatitis scores, sustained proteinuria, and high titers of circulating antinuclear and anti-dsDNA autoantibodies through day 25. The extended model permitted therapeutic validation: intraperitoneal administration of cyclophosphamide at 50 milligrams per kilogram on days 6 and 13 significantly reduced skin lesions, lowered urinary protein excretion, decreased serum autoantibodies, and cleared immune complex deposits from both the epidermal basement membrane zone and renal glomeruli.
The authors next demonstrated that the anatomical extent of epithelial gene deletion directly governs the resulting clinical phenotype. When topical 4-hydroxytamoxifen application was confined to a single ear at 20 microliters daily for five days, the mice developed localized cutaneous lupus-like disease without systemic progression. Treated animals exhibited scaling, erythema, and atrophic plaques by day 10, with histopathology confirming basement membrane IgG deposition and follicular plugs. Notably, single-ear treated mice maintained stable body weight, exhibited no detectable proteinuria, showed normal renal glomerular morphology lacking immune deposits, and displayed normal autoantibody levels and spleen weights, establishing a faithful model of localized cutaneous lupus.
This single-ear cutaneous model also served to evaluate standard dermatological therapies and investigate environmental disease triggers. Topical administration of clobetasol propionate cream at 0.05 percent every two days starting on day 10 resolved cutaneous erythema, desquamation, and follicular plugs while reducing epidermal thickness and basement membrane IgG deposition without causing systemic side effects. Furthermore, when cutaneous-restricted mice were subjected to ultraviolet irradiation across five consecutive days, the light exposure exacerbated local skin damage, stimulated epidermal MX1 and type I interferon production, and triggered rapid systemic transformation marked by severe proteinuria, spleen enlargement, altered T-cell subsets, and autoantibody generation.
Mechanistic single-cell transcriptomic analyses of human discoid lupus and systemic lupus skin biopsies, combined with murine co-culture experiments, explained how perturbed keratinocytes drive systemic immune responses. In human lesions, non-Langerhans dendritic cells accumulated within the epidermis while declining in the dermis, accompanied by elevated epithelial CCL20 expression and high expression of the chemokine receptor CCR7 on epidermal dendritic cells. In vitro assays demonstrated that CCR7-positive dendritic cells purified from lupus lesions potently stimulated the proliferation of naive CD4-positive T cells and preferentially directed their differentiation into inflammatory effector T cell lineages rather than regulatory T cells.
The study authors noted that their immunocompetent C57BL/6 model exhibited complete penetrance in both male and female animals, lacking the pronounced female bias observed in human lupus patients and suggesting that sex hormones may regulate PPAR gamma upstream in humans. In addition, the authors highlighted that while topical therapies and immunosuppressants proved effective in this model, prior clinical trials evaluating systemic PPAR gamma agonists such as pioglitazone demonstrated improvements in vascular and metabolic parameters without altering overall lupus disease activity. The authors concluded that keratinocyte perturbation provides an accessible, tunable platform for dissecting early epithelial triggers and testing interventions across the lupus spectrum.
To establish the molecular foundations of epithelial dysregulation, the researchers evaluated specific gene enrichment metrics across human datasets. Gene Set Enrichment Analysis of differentially expressed transcripts in cutaneous lupus lesions identified significant downregulation of the peroxisome proliferator-activated receptor pathway across three independent cohorts, involving thirteen pathway genes in dataset GSE72535, seven genes in dataset GSE100093, and seven genes in dataset GSE109248. Subsequent single-cell RNA sequencing was conducted on an Illumina NovaSeq6000 platform using commercial droplet-based kits, capturing an average target of ten thousand cells per sample across five to twelve thousand cells. The human profiling aggregated fourteen epidermal cell suspensions, comprising four healthy controls, five discoid lupus, and five systemic lupus samples, alongside sixteen dermal suspensions from four controls, five discoid lupus, and seven systemic lupus patients, thereby permitting comprehensive mapping of epidermal versus dermal dendritic cell behavior.
Isolation and functional testing of immune cell populations relied on rigorous multistep purification protocols. Tail snips collected at postnatal day twenty-one confirmed animal genotypes through alkaline lysis DNA extraction, and experimental cohorts utilized five- to eight-week-old mice with balanced male-to-female sex ratios. Naive CD4-positive T cells were isolated from murine spleens by magnetic cell separation, while dendritic cells underwent extensive negative flow cytometric sorting to deplete confounding lineages. Investigators systematically gated out macrophages and monocytes using CD64 and Ly6C, Langerhans cells with CD207, neutrophils with Ly6G, T cells with CD3, natural killer cells with NK1.1, and B cells with CD19 before isolating CD11c-positive dendritic cells via magnetic beads. In round-bottom culture wells, two hundred thousand naive T cells were incubated with ten thousand purified dendritic cells in the presence of anti-CD3 and anti-CD28 antibodies for five days. Carboxyfluorescein succinimidyl ester tracking confirmed that cutaneous lupus-derived dendritic cells stimulated heightened T-cell proliferation and skewed differentiation toward inflammatory helper subsets.
The investigators also elucidated distinct non-transcriptional regulatory mechanisms governing epithelial immune restraint. In keratinocytes, peroxisome proliferator-activated receptor gamma dampens type I interferon production primarily through direct protein-protein interactions rather than classical nuclear transcriptional activation. Furthermore, the authors observed that elevated CCL20 expression in lesion-associated keratinocytes serves to concentrate CCR7-positive dendritic cells within the epidermal compartment. This localized microenvironmental trapping may act as an intrinsic tissue barrier, temporarily constraining aggressive dendritic cell activity before systemic spillover occurs. The team emphasized that subclinical immune cell infiltration and basement membrane immunoglobulin deposition appear in morphologically normal skin prior to overt pathology, indicating that covert immune breakdown precedes visible lesions. Animal studies maintained unblinded evaluations across randomized cages, with all key experimental findings replicated in at least two independent trials.
Subject of Research: Keratinocyte-driven mouse model of cutaneous and systemic lupus erythematosus
Article Title: Proinflammatory keratinocytes drive a novel mouse model of autoimmunity with systemic and cutaneous lupus erythematosus
Article References: Tian, J., Shi, L., Zhang, D., Yao, X., Lu, J., Zhao, M., & Lu, Q. (2026). Proinflammatory keratinocytes drive a novel mouse model of autoimmunity with systemic and cutaneous lupus erythematosus. Immunity & Inflammation, 2(1), Article 7. https://doi.org/10.1007/s44466-025-00024-y
Image Credits: AI Generated
DOI: 10.1007/s44466-025-00024-y
Keywords: Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Keratinocytes, PPAR gamma, Autoimmunity, Mouse Models, Dendritic Cells, CCR7, Ultraviolet Radiation, Type I Interferons, C57BL/6, Photosensitivity, Proteinuria, Autoantibodies, Gene Knockout, Glomerulonephritis
News Source: Ophelia Keating. (November 21, 2026). Keratinocyte Defects Trigger Cutaneous and Systemic Lupus in Mouse Model. Scienmag.



